China approves its first biosimilar, a Rituxan copy from Fosun’s IPO-heading Henlius
admin 25th February 2019 Uncategorised 0Roche’s patent cliffs to its big three cancer blockbusters have expanded to China, as Chinese regulators have approved a copycat to lymphoma drug Rituxan. More: China approves its first biosimilar, a Rituxan copy from Fosun’s IPO-heading Henlius Source: fierce
read more